UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 155

Sortiert nach

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

The lancet oncology, 2016-07, Vol.17 (7), p.984-993

2016

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

Cancer treatment reviews, 2013-12, Vol.39 (8), p.839-850

2013

Volltextzugriff (PDF)

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

Expert opinion on biological therapy, 2011-12, Vol.11 (12), p.1663-1668

2011

Volltextzugriff (PDF)

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors

Journal of proteomics, 2013-10, Vol.91, p.286-296

2013

Volltextzugriff (PDF)

Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10

Journal of clinical oncology, 2007-04, Vol.25 (12), p.1553-1561

2007

Volltextzugriff (PDF)

Lung Cancer in a U.S. Population with Low to Moderate Arsenic Exposure

Environmental health perspectives, 2009-11, Vol.117 (11), p.1718-1723

2009

Volltextzugriff (PDF)

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

The New England journal of medicine, 2005-06, Vol.352 (25), p.2589-2597

2005

Volltextzugriff (PDF)

Taxane‐Platinum Combinations in Advanced Non‐Small Cell Lung Cancer: A Review

The oncologist (Dayton, Ohio), 2004-06, Vol.9 (S2), p.16-23

Rigas, James R.

2004

Volltextzugriff (PDF)

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3238-3247

2004

Volltextzugriff (PDF)

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-11, Vol.25 (33), p.5240-5247

2007

Volltextzugriff (PDF)

Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark

PloS one, 2023-04, Vol.18 (4), p.e0284037-e0284037

2023

Volltextzugriff (PDF)

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer

Future oncology (London, England), 2019-09, Vol.15 (26), p.3003-3014

2019

Volltextzugriff (PDF)

Adjuvant vinorelbine and cisplatin in elderly patients : National cancer institute of Canada and intergroup study JBR. 10

Journal of clinical oncology, 2007-04, Vol.25 (12), p.1553-1561

2007

Volltextzugriff (PDF)

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1938-1949

2010

Volltextzugriff (PDF)

Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

Clinical and applied thrombosis/hemostasis, 2006-10, Vol.12 (4), p.389-396

2006

Volltextzugriff (PDF)

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

Cancer, 2015-12, Vol.121 (23), p.4165-4172

2015

Volltextzugriff (PDF)

Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2007-06, Vol.2 (6), p.S77-S85

2007

Volltextzugriff (PDF)

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

Cancer prevention research (Philadelphia, Pa.), 2011-06, Vol.4 (6), p.818-828

2011

Volltextzugriff (PDF)

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-01, Vol.6 (1), p.139-147

2011

Volltextzugriff (PDF)

A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1794-1800

2007

Volltextzugriff (PDF)

Pemetrexed in advanced non-small-cell lung cancer

Expert opinion on pharmacotherapy, 2010-06, Vol.11 (8), p.1387-1402

2010

Volltextzugriff (PDF)

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade® ) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2010-04, Vol.68 (1), p.89-93

2010

Volltextzugriff (PDF)

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

Chemotherapy (Basel), 2012-01, Vol.58 (4), p.321-329

2012

Volltextzugriff (PDF)

Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer

Lung, 2013-06, Vol.191 (3), p.265-270

2013

Volltextzugriff (PDF)

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

Cancer management and research, 2019-01, Vol.11, p.9469-9481

2019

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Englisch
(155)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(85)
Science & Technology
(82)
Life Sciences & Biomedicine
(77)
Female
(53)
Male
(52)
Oncology
(47)
Biological And Medical Sciences
(45)
Medical Sciences
(45)
Middle Aged
(43)
Aged
(42)
Lung Neoplasms - Drug Therapy
(37)
Adult
(36)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(35)
Chemotherapy
(30)
Pharmacology. Drug Treatments
(25)
Antineoplastic Agents
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Non-Small Cell Lung Cancer
(18)
Aged, 80 And Over
(17)
Lung Neoplasms - Pathology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors

Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10

Lung Cancer in a U.S. Population with Low to Moderate Arsenic Exposure

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Taxane‐Platinum Combinations in Advanced Non‐Small Cell Lung Cancer: A Review

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer

Adjuvant vinorelbine and cisplatin in elderly patients : National cancer institute of Canada and intergroup study JBR. 10

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer

Pemetrexed in advanced non-small-cell lung cancer

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade® ) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

Suchergebnisse filtern